Real-world data show reduction in use of urate-lowering therapy among people with type 2 diabetes using SGLT2 inhibitors.

According to the World Health Organisation (WHO), over 350 million people globally suffer from arthritis, and despite ...

Discover the causes, symptoms, and treatment options for gout—a painful form of arthritis predominantly affecting men.

For patients with nephrolithiasis, sodium-glucose cotransporter-2 (SGLT-2) inhibitor use is associated with a reduction in recurrence.

Efforts to combat hyperuricemia may find help from gut microbes, according to Dylan Dodd, MD, PhD, who spoke at the annual ...

WHEN Thomas Tuchel was unceremoniously sacked by Chelsea he looked for a factory reset. The England boss, 51, found it in ...

Protalix BioTherapeutics, Inc. (NYSE: PLX), a biopharmaceutical company specializing in the development, production, and commercialization of recombinant therapeutic proteins, recently disclosed its ...

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

Common treatments, such as statins, are effective at lowering LDL cholesterol and have also shown to reduce inflammation, ...

Amgen today announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of Rheumatology (ACR) Convergence 2024 conference in Washington, D.C., ...

"We are pleased to report that all eight cohorts of our phase I first-in-human study of PRX-115, our recombinant uricase candidate being developed for the treatment of uncontrolled gout, are now ...

Like a fire alarm sending signals to evacuate a smoky building, the immune system has internal guards to help the body sense ...